Payment overview · 2025
General Payments
$885.45
42 reported records · 20 companies
Healthcare provider profile · identity verified
Nadeem Ansari, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BOURBONNAIS, IL · NPI 1073651808
Verified facts
What the public records show
CMS Open Payments records show Nadeem Ansari, MD received $885.45 in general payments during 2025 across 42 reported records.
Novo Nordisk Inc accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $189.43 | 21.4% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $100.92 | 11.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.46 | 11.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.02 | 7.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.84 | 7.1% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $47.85 | 5.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.78 | 5.3% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $39.72 | 4.5% | 1 | 2025 |
| Iovance Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $24.10 | 2.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.88 | 2.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.94 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.61 | 2.3% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $20.34 | 2.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.96 | 2.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.85 | 2.2% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.91 | 2.0% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $17.91 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.64 | 2.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.16 | 1.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.13 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $885.45 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $80.98 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $78.45 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.75 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $52.75 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $52.75 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $47.85 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.28 | 2 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $39.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $29.22 | 1 | 2025 |
Source payment records
|
|||||
| Amtagvi Normalized: amtagvi |
Drug | Iovance Biotherapeutics, Inc. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 75 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 81 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 904 | 272 |
| Amlodipine Besylate | Amlodipine Besylate | 634 | 193 |
| Levothyroxine Sodium | Levothyroxine Sodium | 617 | 154 |
| Losartan Potassium | Losartan Potassium | 593 | 165 |
| Pantoprazole Sodium | Pantoprazole Sodium | 463 | 142 |
| Metoprolol Succinate | Metoprolol Succinate | 407 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 314 | 98 |
| Duloxetine Hcl | Duloxetine Hcl | 292 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 73 |
| Lisinopril | Lisinopril | 250 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 234 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 71 |
| Metformin Hcl Er | Metformin Hcl | 215 | 62 |
| Trazodone Hcl | Trazodone Hcl | 212 | 62 |
| Gabapentin | Gabapentin | 205 | 53 |
| Potassium Chloride | Potassium Chloride | 205 | 60 |
| Montelukast Sodium | Montelukast Sodium | 194 | 54 |
| Eliquis | Apixaban | 173 | 40 |
| Furosemide | Furosemide | 165 | 58 |
| Valsartan | Valsartan | 149 | 59 |
| Carvedilol | Carvedilol | 145 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 145 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 56 |
| Omeprazole | Omeprazole | 138 | 45 |
| Donepezil Hcl | Donepezil Hcl | 121 | 32 |
| Spironolactone | Spironolactone | 119 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 25 |
| Tramadol Hcl | Tramadol Hcl | 110 | 29 |
| Allopurinol | Allopurinol | 107 | 31 |
| Mirtazapine | Mirtazapine | 103 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 34 |
| Clonazepam | Clonazepam | 87 | 18 |
| Sertraline Hcl | Sertraline Hcl | 84 | 28 |
| Torsemide | Torsemide | 83 | 28 |
| Jardiance | Empagliflozin | 81 | 19 |
| Farxiga | Dapagliflozin Propanediol | 75 | 16 |
| Ezetimibe | Ezetimibe | 74 | 27 |
| Mounjaro | Tirzepatide | 74 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 22 |
| Ozempic | Semaglutide | 72 | 14 |
| Bupropion Xl | Bupropion Hcl | 71 | 29 |
| Chlorthalidone | Chlorthalidone | 69 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 69 | 23 |
| Myrbetriq | Mirabegron | 65 | 18 |
| Metformin Hcl | Metformin Hcl | 64 | 24 |
| Memantine Hcl | Memantine Hcl | 63 | 20 |
| Warfarin Sodium | Warfarin Sodium | 63 | 15 |
| Azelastine Hcl | Azelastine Hcl | 61 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 57 | 14 |
| Famotidine | Famotidine | 56 | 14 |
| Irbesartan | Irbesartan | 56 | 15 |
| Pregabalin | Pregabalin | 55 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | 18 |
| Synthroid | Levothyroxine Sodium | 52 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 49 | 28 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | 15 |
| Meloxicam | Meloxicam | 47 | 16 |
| Alprazolam | Alprazolam | 46 | 13 |
| Dutasteride | Dutasteride | 46 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 43 | 18 |
| Risedronate Sodium | Risedronate Sodium | 43 | 12 |
| Lorazepam | Lorazepam | 41 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 40 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 15 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | 11 |
| Prednisone | Prednisone | 37 | 23 |
| Celecoxib | Celecoxib | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 24 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 17 | 13 |
| Fluconazole | Fluconazole | 17 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 13 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $885.45 · 42 records | Novo Nordisk Inc | AREXVY, Amtagvi, Auvelity, BREZTRI, CREON, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, ImmunoCAP, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, MITRACLIP, MOUNJARO, NUPLAZID, NURTEC ODT, Ozempic, QULIPTA, REXULTI, REZDIFFRA, SHINGRIX, UBRELVY, VOWST, VRAYLAR, Wegovy, XYWAV, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error